Stephanie Baum is the Director of Special Projects for MedCityNews. She graduated from Franklin & Marshall College in Pennsylvania and has worked across radio, print and video. She's worked for Dow Jones & Co., The Legal Intelligencer, The Christian Science Monitor, AP Radio's London bureau, and United Business Media. LinkedIn: https://www.linkedin.com/in/stephanie-baum-24a7406/| MedCity News
Illumina has decided against further appeals of U.S. and European antitrust litigation challenging its acquisition of liquid biopsy company Grail. Illumina expects to have terms of the divestiture set by the end of the second quarter of 2024.| MedCity News
Illumina must pay a €432 million fine for closing its Grail acquisition before the European Commission finished its inquiry into the tie-up. The penalty is the maximum amount the regulator can impose on a company for breaching European merger rules.| MedCity News
The lack of access to quality healthcare is often cited as the reason for maternal health disparities. But these issues go beyond access, according to Bayo Curry-Winchell, MD, founder of Beyond Clinical Walls and urgent care medical director at St. Mary’s Health Network.| MedCity News
Cresilon snagged its second FDA clearance for human use. The FDA granted 510(k) clearance to Traumagel, the startup’s gel that can stop bleeding in just seconds, for temporary external use to control moderate to severe bleeding.| MedCity News
NOWDiagnostics’ First To Know has FDA De Novo marketing authorization as a new test for syphilis. The at-home product needs only a single drop of blood to test for this sexually transmitted infection.| MedCity News
